EMERGENT BIOSOLUTIONS INC (EBS)

US29089Q1058 - Common Stock

2.85  +0.11 (+4.01%)

Premarket: 2.85 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
1.555B
40.63%
1.793B
15.26%
1.118B
-37.66%
1.064B
-4.79%
EBITDA
YoY % growth
594.6M
164.50%
559.6M
-5.89%
-20M
-103.57%
71.407M
457.04%
N/AN/A
EBIT
YoY % growth
480.1M
320.77%
435.8M
-9.23%
-163.3M
-137.47%
-689.78M
-322.40%
N/AN/A
Operating Margin
30.87%24.31%-14.61%-64.83%N/AN/A
EPS
YoY % growth
7.85
183.39%
6.00
-23.57%
-2.26
-137.67%
-4.43
-96.04%
N/AN/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth
-0.19
38.10%
Revenue
Q2Q % growth
296.47M
-10.35%
EBITDA
Q2Q % growth
25.25M
EBIT
Q2Q % growth
5.791M
109.92%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth
-0.48
62.20%
-0.23-0.25-112.80%
Q2 2023
Q2Q % growth
-1.06
-23.26%
-0.49-0.57-115.65%
Q1 2023
Q2Q % growth
-3.17
-1,861.11%
-1.25-1.92-153.11%
Q4 2022
Q2Q % growth
-0.31
-106.89%
0.04-0.35-797.57%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth
270.5M
12.71%
239.81M30.69M12.80%
Q2 2023
Q2Q % growth
502.2M
106.92%
218.33M283.87M130.02%
Q1 2023
Q2Q % growth
165.1M
-46.31%
144.71M20.39M14.09%
Q4 2022
Q2Q % growth
330.7M
-54.27%
299.59M31.11M10.38%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS-218.75% -178.08% 0% -18.56%
Revenue4% -0.68% 0% 0.19%